PT771813E - Fosfonatos de alquilxantina e fosfinoxidos de alquilxantina e sua utilizacao como medicamentos - Google Patents

Fosfonatos de alquilxantina e fosfinoxidos de alquilxantina e sua utilizacao como medicamentos

Info

Publication number
PT771813E
PT771813E PT96116861T PT96116861T PT771813E PT 771813 E PT771813 E PT 771813E PT 96116861 T PT96116861 T PT 96116861T PT 96116861 T PT96116861 T PT 96116861T PT 771813 E PT771813 E PT 771813E
Authority
PT
Portugal
Prior art keywords
alkyl
xanthin
cycloalkyl
phosphonic acid
phosphonates
Prior art date
Application number
PT96116861T
Other languages
English (en)
Inventor
Ismahan Okyayuz-Baklouti
Hiristo Anagnostopulos
Stefan Mullner
Gunter Billen
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PT771813E publication Critical patent/PT771813E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96116861T 1995-11-02 1996-10-21 Fosfonatos de alquilxantina e fosfinoxidos de alquilxantina e sua utilizacao como medicamentos PT771813E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19540798A DE19540798A1 (de) 1995-11-02 1995-11-02 Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
US08/741,591 US5728686A (en) 1995-11-02 1996-10-31 Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
PT771813E true PT771813E (pt) 2002-07-31

Family

ID=26020012

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96116861T PT771813E (pt) 1995-11-02 1996-10-21 Fosfonatos de alquilxantina e fosfinoxidos de alquilxantina e sua utilizacao como medicamentos

Country Status (10)

Country Link
US (1) US5728686A (pt)
EP (1) EP0771813B1 (pt)
JP (1) JP4150086B2 (pt)
CN (1) CN1158855A (pt)
AT (1) ATE212029T1 (pt)
CA (1) CA2189222A1 (pt)
DE (2) DE19540798A1 (pt)
DK (1) DK0771813T3 (pt)
ES (1) ES2170825T3 (pt)
PT (1) PT771813E (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
GB2333041A (en) * 1998-01-13 1999-07-14 Johnson & Johnson Medical Ltd Wound Composition
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
FR2804867B1 (fr) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
WO2003008396A1 (fr) * 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Derive d'oxazine actif sur le plan optique
DK1509525T5 (da) * 2002-05-31 2007-07-30 Schering Corp Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor
EP1719772A1 (en) * 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2007141029A1 (en) * 2006-06-08 2007-12-13 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Specific protease inhibitors and their use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
SE8801729D0 (sv) * 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
DE59304710D1 (de) * 1992-02-22 1997-01-23 Hoechst Ag Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
CA2126601A1 (en) * 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
ATE220549T1 (de) * 1994-12-29 2002-08-15 Univ California Verbindungen zur hemmung der ceramid vermittelten signalübertragung

Also Published As

Publication number Publication date
JPH09124671A (ja) 1997-05-13
US5728686A (en) 1998-03-17
EP0771813B1 (de) 2002-01-16
DK0771813T3 (da) 2002-04-29
ES2170825T3 (es) 2002-08-16
DE19540798A1 (de) 1997-05-07
JP4150086B2 (ja) 2008-09-17
DE59608590D1 (de) 2002-02-21
ATE212029T1 (de) 2002-02-15
EP0771813A1 (de) 1997-05-07
CN1158855A (zh) 1997-09-10
MX9605315A (es) 1997-05-31
CA2189222A1 (en) 1997-05-03

Similar Documents

Publication Publication Date Title
PT771813E (pt) Fosfonatos de alquilxantina e fosfinoxidos de alquilxantina e sua utilizacao como medicamentos
ATE302180T1 (de) Zwischenprodukte zur herstellung von non-peptiden retroviralproteasehemmenden verbindungen
NZ511067A (en) Serine protease inhibiting isoquinoline derivatives and their use for treating or preventing thrombin-mediated or thrombin-associated diseases
BG101402A (en) Apoliprotein-b synthesis inhibitors
MA26457A1 (fr) Vinylpyrrolidone-cephalosporines a substituants basiques, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
WO1992010504A3 (en) Phosphonic acid derivatives useful as antiinflammatory agents
FR2663328B1 (fr) Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
HUT38921A (en) Process for producing antitussive and slime-regulating 2-substituted thiazolidine derivatives and pharmaceutical compositions containing them as active agents
IE940342L (en) Use of 2,2-dimethychromene derivatives in the treatment of asthma
EP0850911A3 (en) Process for producing triazine compounds
NO306615B1 (no) Kinoksaliner, deres anvendelse samt medikamenter inneholdende kinoksalinene
DE69328900D1 (de) Verfahren zur Reinigung von Teppichen
ATE164163T1 (de) Dialkyl (dialkoxyphosphinyl)methyl phosphate als antientzündungsmittel
ES2145561T3 (es) Derivados bencilo(s) sustituido(s) de polialquilenpoliamidas y su utilizacion en composiciones cosmeticas y farmaceuticas.
NL300068I1 (nl) Nieuwe werkwijze voor de bereiding van 20-keto-21alfa-hydroxysteroïden en daarbij optreden tussenprodukten.
ES8602002A1 (es) Procedimiento para preparar nuevas 4-fenil-tetrahidrofurano-(2,3-c)priridinas
AU4842297A (en) New N-benzylpiperazine compounds, process for their preparation and the pharmaceutical compositions which contain them
ES2038693T3 (es) Nuevos acidos aminometanodifosfonicos substituidos.
ES483978A1 (es) Procedimiento para la obtencion de derivados de acido hidro-xialcanoico
DE59606328D1 (de) Verfahren zur Herstellung von gegebenenfalls 2-substituierten 5-Chlor-imidazol-4-carbaldehyden
ES2168116T3 (es) Nuevos productos intermedios para la sintesis de compuestos de bisfosfina.
JPS6463517A (en) Antianxiety composition
DE69019786T2 (de) Antiherpes-Tetrapeptid-Derivate mit einer substituierten Seitenkette aus Asparaginsäure.
ATE122352T1 (de) 3-(3-ethyl-1,2,4-oxadiazol-5-yl)-1- azabicycloheptan, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zubereitungen.
EP0177897A3 (en) Antibacterial 7beta-heterocyclic-cephem